Ponatinib in the leukemia world: Why a reevaluation is necessary for Philadelphia chromosome-positive patients with T315I mutation

Expert Review of Hematology

Volumn 7, Issue 5, 2014, Pages 513-515

  Goodrich, Angelina Daisy ^a  

^a UNIVERSITY OF NEVADA   (United States)

Author keywords

leukemia; Philadelphia chromosome; ponatinib; T315I mutation; tyrosine kinase inhibitor

Indexed keywords

ANTICOAGULANT AGENT; BCR ABL PROTEIN; IMATINIB; ORPHAN DRUG; PHOSPHOTRANSFERASE INHIBITOR; PONATINIB; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE;

DRUG APPROVAL; DRUG BINDING SITE; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; LEUKEMIA; PERSONALIZED MEDICINE; PHILADELPHIA CHROMOSOME POSITIVE CELL; REVIEW; RISK MANAGEMENT; STEREOSPECIFICITY; UNITED STATES; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; PHILADELPHIA 1 CHROMOSOME; SINGLE NUCLEOTIDE POLYMORPHISM;

BLOOD COAGULATION; CLINICAL TRIALS AS TOPIC; FUSION PROTEINS, BCR-ABL; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHILADELPHIA CHROMOSOME; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; PYRIDAZINES;

EID: 84907049304     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.958465     Document Type: Review

References (11)

1. Drugs@FDA. Approval history, letters, review, and related documents on ponatinib. Available from: www. accessdata. fda. gov/ scripts/cder/drugsatfda/index. cfm? fuseaction=Search. DrugDetails [Last accessed 21 July 2014]
2. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003;138(10):819-30
3. Zhou T, Commodore L, Huang WS, et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 2011; 77(1):1-11
4. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23(6):1054-61
5. Soverini S, De Benedittis C, Papayannidis C, et al. Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer 2014;120(7):1002-9
6. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16(5):401-12
7. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367(22):2075-88
8. Senior M. FDA halts then allows sales of Ariad's leukemia medication. In: Nature Biotechnology. United States: 2014. pp 9-11
9. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369(19):1783-96
10. Hochhaus A, Pinilla-Ibarz J, Kim D-W, et al. Clinical impact of dose modification and dose intensity on response to ponatinib on patients with Philadelphia chromosome-positive leukemias. J Clin Oncology 2014;32(5 suppl): abstr 7084
11. Rix U, Colinge J, Blatt K, et al. A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL. PLoS One 2013;8(10): e77155